Cancer in Tunisia

IARC estimates 16,332 new cancer cases and 9,059 cancer deaths in Tunisia in 2024; the commonest new cancers are breast, trachea, bronchus and lung and colorectum. This page is assembled automatically from OnCo's data: 4 trials with a site there, 1 institution and 1 person, and says what OnCo does not yet hold.

Cancer figures, GLOBOCAN 2024

Compare countries →

New cases

16,332

all cancers

Deaths

9,059

all cancers

Incidence rate

105.7

per 100,000, age-standardised

Mortality rate

58.0

per 100,000, age-standardised

Cumulative risk

11.3%

of a cancer by age 74

Population

12,277,112

IARC, 2024

Most new cases

Site	New cases	Rate	OnCo page
Breast	2,535	31.9	Triple-negative breast cancer (TNBC), HR-positive / HER2-negative breast cancer, HER2-positive breast cancer
Trachea, bronchus and lung	2,049	13.0	Lung cancer (all types), Non-small-cell lung cancer, Small-cell lung cancer
Colorectum	1,813	11.5	Colorectal cancer
Bladder	1,383	8.6	Bladder & urothelial cancer
Prostate	777	10.4	Prostate cancer
Non-Hodgkin lymphoma	664	4.4	Non-Hodgkin lymphoma (all types), Diffuse large B-cell lymphoma
Stomach	629	4.0	Gastric & gastro-oesophageal junction cancer
Larynx	425	2.7
Pancreas	377	2.4	Pancreatic ductal adenocarcinoma
Leukaemia	373	2.9	Acute myeloid leukaemia, Acute lymphoblastic leukaemia, Chronic lymphocytic leukaemia

Most deaths

Site	Deaths	Rate	OnCo page
Trachea, bronchus and lung	1,671	10.6	Lung cancer (all types), Non-small-cell lung cancer, Small-cell lung cancer
Breast	947	11.8	Triple-negative breast cancer (TNBC), HR-positive / HER2-negative breast cancer, HER2-positive breast cancer
Bladder	782	4.8	Bladder & urothelial cancer
Colorectum	772	4.9	Colorectal cancer
Stomach	436	2.8	Gastric & gastro-oesophageal junction cancer
Pancreas	362	2.3	Pancreatic ductal adenocarcinoma
Prostate	298	4.0	Prostate cancer
Larynx	296	1.9
Brain, central nervous system	290	2.1	Glioma & glioblastoma
Non-Hodgkin lymphoma	282	1.8	Non-Hodgkin lymphoma (all types), Diffuse large B-cell lymphoma

Incidence: method 2b, subnational rates applied to the 2024 population.
Mortality: method 3c, national incidence estimates applied to model-based mortality-to-incidence ratios (registry survival data).
Rates are age-standardised per 100,000 (World standard population), both sexes, all ages. Non-melanoma skin cancer is left out of the site lists, as on the deep dives. IARC lists the country as “Tunisia”, in Northern Africa (Africa), High HDI, lower middle income.
Source: Ervik M, Laversanne M, Lam F, Colombet M, Ferlay J, Filho AM, Bray F (2026). Global Cancer Observatory: Cancer Today (2024 estimates, version 1.0). Lyon, France: International Agency for Research on Cancer. https://gco.iarc.who.int/today, read through the IARC API on 2026-11-04.

Trials with a site here

4 trials in OnCo · 2 recruiting overall

4 trials

Trial			Lead sponsor
A Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast Cancer NCT05894239	Phase 3	Recruiting	Hoffmann-La Roche	192	2026-09-21
A Study to Evaluate Long-term Safety in Participants Who Have Participated in Other Luspatercept (ACE-536) Clinical Trials NCT04064060	Phase 3	Recruiting	Celgene	143	2026-07-01
A Study to Compare Pharmacokinetics, Efficacy, Safety, and Immunogenicity of MB12 (Proposed Pembrolizumab Biosimilar) to Keytruda® in Non-small Cell L NCT06687369	Phase 3	Active not recruiting	mAbxience Research S.L.	173	2026-09-10
PROSELICA NCT01308580	Phase 3	Completed	Sanofi	172	2017-04-17

Trial records in OnCo whose ClinicalTrials.gov entry lists at least one site in Tunisia, captured 2026-10-07 to 2026-10-07. Recruiting first, then the most recently updated. The status is the study's overall status; whether a site in Tunisia is open is on the registry page, under Contacts and Locations.

Institutions, companies and people

1 institution

Institut Salah Azaïez

1 person

People whose main affiliation in OnCo is an institution or company in Tunisia.

Senda Tounsi

Approvals

OnCo records approvals for United States, European Union, United Kingdom, Japan, China, Australia and India. Tunisia is not one of them, so no approval in OnCo speaks for it. See the approvals by region matrix for what is held.

What OnCo does not yet hold

No registry figures. The figures above are IARC's estimates; OnCo has not read Tunisia's own cancer registry, its survival figures or its stage at diagnosis.
No payer detail: who pays for cancer care in Tunisia, what a patient pays, and which medicines are reimbursed.
No regulator detail: the national medicines regulator, its approval routes and its decisions.
No national cancer plan, guideline, screening schedule or treatment-centre list read from Tunisia's own sources.

A deep dive for Tunisia is ranked 60 of 60 in the country coverage queue (November 2026), which ranks countries without a page by cases, deaths, research output and population. Know a source? Suggest an edit.

Sources and machine-readable data

IARC Global Cancer Observatory, GLOBOCAN 2024: Cancer Today.
ClinicalTrials.gov study records, courtesy of the US National Library of Medicine, as captured in each trial record.
OnCo records: each chip and card opens a record with its own sources.
This page as JSON: /api/v1/countries/tn.json; every country: /api/v1/countries.json.